Physician profile
Daniel N Smiley
NPI 1033176870
$7,998.50
in general payments reported to CMS, 2019-2025
43 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,766 · 2020: $369 · 2021: $353 · 2022: $525 · 2023: $1,504 · 2024: $1,874 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948 · Education: $37.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,947.89 |
| Education | $37.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,258.22 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,118.77 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,033.09 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $779.26 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $342.06 | 2019-2024 | Zeposia |
| Gilead Sciences, INC. | $313.82 | 2019-2025 | |
| Ardelyx, INC. | $291.47 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $286.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $178.54 | 2024-2025 | Zenpep |
| Lucid Diagnostics INC. | $176.42 | 2025 | |
| Phathom Pharmaceuticals, INC. | $164.87 | 2024-2025 | Voquezna |
| Genzyme Corporation | $161.35 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $160.28 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $158.74 | 2024-2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $149.99 | 2023 | Terlivaz |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Smiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.